AR074350A1 - Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina - Google Patents

Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina

Info

Publication number
AR074350A1
AR074350A1 ARP090104418A ARP090104418A AR074350A1 AR 074350 A1 AR074350 A1 AR 074350A1 AR P090104418 A ARP090104418 A AR P090104418A AR P090104418 A ARP090104418 A AR P090104418A AR 074350 A1 AR074350 A1 AR 074350A1
Authority
AR
Argentina
Prior art keywords
phenyl
fluorophenoximethyl
pipiridine
compound
crystal form
Prior art date
Application number
ARP090104418A
Other languages
English (en)
Inventor
Miroslav Rapta
Lori Jean Patterson
Robert Chao
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR074350A1 publication Critical patent/AR074350A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Composiciones farmacéuticas que comprenden la sal cristalina, procesos e intermediarios para preparar la sal cristalina y métodos para usar la sal cristalina para el tratamiento del dolor entre otras enfermedades. Reivindicación 1: Una sal de clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]-pipiridina caracterizada porque presenta un patrón de difracción de rayos X en polvo que comprende picos de difracción en valores 2theta de 4,44ñ0,20, 10,22ñ0,20, 17,16ñ0,20 y 21,78ñ0,20.
ARP090104418A 2008-11-14 2009-11-13 Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina AR074350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14

Publications (1)

Publication Number Publication Date
AR074350A1 true AR074350A1 (es) 2011-01-12

Family

ID=41666409

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP090104418A AR074350A1 (es) 2008-11-14 2009-11-13 Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina
ARP090104419A AR074128A1 (es) 2008-11-14 2009-11-13 Derivados de 4-[2-(2-fluorofenoximetil)fenil] piperidina, composiciones farmaceuticas que los contienen, metodo de preparacion, compuestos intermediarios de dicho proceso y uso de los mismos para el tratamiento de dolores neuropaticos, mal de alzheimer y otras enfermedades relacionadas con el snc.
ARP190101607A AR114965A2 (es) 2008-11-14 2019-06-11 Sal de clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP090104419A AR074128A1 (es) 2008-11-14 2009-11-13 Derivados de 4-[2-(2-fluorofenoximetil)fenil] piperidina, composiciones farmaceuticas que los contienen, metodo de preparacion, compuestos intermediarios de dicho proceso y uso de los mismos para el tratamiento de dolores neuropaticos, mal de alzheimer y otras enfermedades relacionadas con el snc.
ARP190101607A AR114965A2 (es) 2008-11-14 2019-06-11 Sal de clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina

Country Status (29)

Country Link
US (23) US8247433B2 (es)
EP (3) EP2358676B1 (es)
JP (6) JP5598798B2 (es)
KR (3) KR101656338B1 (es)
CN (3) CN102209712B (es)
AR (3) AR074350A1 (es)
AU (3) AU2009313948B2 (es)
BR (3) BRPI0921593B8 (es)
CA (3) CA2739992C (es)
CL (2) CL2011001088A1 (es)
CO (2) CO6361988A2 (es)
CY (3) CY1113622T1 (es)
DK (3) DK2358675T3 (es)
ES (3) ES2401224T3 (es)
HK (3) HK1160448A1 (es)
HR (3) HRP20120897T1 (es)
IL (2) IL212230A (es)
MX (3) MX2011005088A (es)
MY (2) MY151229A (es)
NZ (2) NZ592543A (es)
PL (3) PL2358674T3 (es)
PT (3) PT2358674E (es)
RU (2) RU2503662C2 (es)
SG (1) SG171311A1 (es)
SI (3) SI2358675T1 (es)
SM (3) SMT201200063B (es)
TW (3) TWI441810B (es)
WO (3) WO2010056939A1 (es)
ZA (1) ZA201103495B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247433B2 (en) 2008-11-14 2012-08-21 Theravance, Inc. Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
US8778949B2 (en) 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
RU2012149695A (ru) * 2010-04-22 2014-05-27 Тереванс, Инк. Комбинация ингибитора обратного захвата серотонина и норэпинефрина и опиодного агониста для лечения боли
JP6277121B2 (ja) 2011-03-22 2018-02-07 アドヴィナス・セラピューティックス・リミテッド 置換された縮合三環式化合物、その組成物および医学的応用
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
AU2017321016B2 (en) * 2016-08-30 2020-04-23 Theravance Biopharma R&D Ip, Llc Compound for use in the treatment of neurogenic orthostatic hypotension
WO2019232010A1 (en) 2018-06-01 2019-12-05 Theravance Biopharma R&D Ip, Llc PROCESS FOR PREPARING 2-(1-(tert-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID
AU2023241617A1 (en) 2022-03-28 2024-09-05 Theravance Biopharma R&D Ip, Llc Ampreloxetine for use for treating multiple system atrophy
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
JP2002520316A (ja) * 1998-07-10 2002-07-09 アストラゼネカ・アクチエボラーグ ニューロキニン受容体アンタゴニストとしてのｎ−置換ナフタレンカルボキサミド
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
SK13752001A3 (sk) * 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
US6630504B2 (en) * 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7384941B2 (en) * 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
ZA200505031B (en) * 2003-04-04 2006-09-27 Lundbeck & Co As H 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahy-dropyridine derivatives as serotonin reuptake inhibitors
PT1635828E (pt) * 2003-04-04 2008-07-01 Lundbeck & Co As H Derivados de 4-(2-feniloxifenil) piperidina ou de 1,2,3,6-tetrahidropiridina como inibidores da recaptação da serotonina
DK1638933T3 (da) * 2003-06-17 2008-07-28 Pfizer N-pyrrolidin-3-yl-amid-derivater som serotonin- og noradrenalin-genoptagelses inhibitorer
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
CA2553289A1 (en) * 2004-01-13 2005-07-28 Pfizer Inc. Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors
US20070072859A1 (en) * 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
GB0505437D0 (en) * 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
US20100120858A1 (en) 2006-08-23 2010-05-13 Pfizer Inc. Piperidine Derivatives
JP2010512304A (ja) * 2006-09-27 2010-04-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレータとしてのアシル化ピペリジン誘導体
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
US8247433B2 (en) 2008-11-14 2012-08-21 Theravance, Inc. Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
US8778949B2 (en) 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
AU2017321016B2 (en) * 2016-08-30 2020-04-23 Theravance Biopharma R&D Ip, Llc Compound for use in the treatment of neurogenic orthostatic hypotension

Also Published As

Publication number Publication date
CN102216271B (zh) 2013-09-25
US20190134019A1 (en) 2019-05-09
KR20110082196A (ko) 2011-07-18
US20180289687A1 (en) 2018-10-11
DK2358675T3 (da) 2013-01-14
US20140057944A1 (en) 2014-02-27
CA2742105A1 (en) 2010-05-20
SMT201200065B (it) 2013-03-08
EP2358675B1 (en) 2012-10-03
WO2010056941A1 (en) 2010-05-20
MX2011005090A (es) 2011-09-06
PL2358674T3 (pl) 2013-06-28
AU2009313949A1 (en) 2010-05-20
US20160184288A1 (en) 2016-06-30
KR20110082197A (ko) 2011-07-18
CA2742114C (en) 2016-09-13
CN102216272A (zh) 2011-10-12
CL2011001088A1 (es) 2011-10-14
CA2739992C (en) 2016-09-20
JP2014101384A (ja) 2014-06-05
JP2012508761A (ja) 2012-04-12
NZ592413A (en) 2013-02-22
US10722504B2 (en) 2020-07-28
US20200000792A1 (en) 2020-01-02
US20240316024A1 (en) 2024-09-26
CO6361988A2 (es) 2012-01-20
BRPI0921593A2 (pt) 2015-08-18
BRPI0921595B1 (pt) 2020-10-13
US20200316047A1 (en) 2020-10-08
CA2742105C (en) 2016-09-13
US20200316048A1 (en) 2020-10-08
US8802857B2 (en) 2014-08-12
AU2009313951A1 (en) 2010-05-20
US10034870B2 (en) 2018-07-31
ZA201103495B (en) 2012-01-25
TW201024264A (en) 2010-07-01
HK1160449A1 (en) 2012-08-17
JP5529150B2 (ja) 2014-06-25
SI2358676T1 (sl) 2013-01-31
PL2358676T3 (pl) 2013-03-29
US8592596B2 (en) 2013-11-26
EP2358674B1 (en) 2013-01-02
US20100125092A1 (en) 2010-05-20
AR114965A2 (es) 2020-11-11
US9675599B2 (en) 2017-06-13
US11596624B2 (en) 2023-03-07
CY1113622T1 (el) 2016-06-22
BRPI0921595B8 (pt) 2021-05-25
WO2010056939A1 (en) 2010-05-20
JP2012508760A (ja) 2012-04-12
MX2011005089A (es) 2011-07-29
US20120277438A1 (en) 2012-11-01
KR101656338B1 (ko) 2016-09-09
WO2010056938A1 (en) 2010-05-20
IL212230A (en) 2014-12-31
DK2358676T3 (da) 2013-01-14
CL2011001093A1 (es) 2011-09-02
KR101656339B1 (ko) 2016-09-09
US10576073B2 (en) 2020-03-03
DK2358674T3 (da) 2013-04-08
CN102209712B (zh) 2016-04-06
US20160022660A1 (en) 2016-01-28
JP2012508759A (ja) 2012-04-12
US20230201181A1 (en) 2023-06-29
US20140323735A1 (en) 2014-10-30
US9187423B2 (en) 2015-11-17
JP2014098033A (ja) 2014-05-29
HK1160452A1 (en) 2012-08-17
US20220087995A1 (en) 2022-03-24
MY151229A (en) 2014-04-30
US10206913B2 (en) 2019-02-19
US20140045892A1 (en) 2014-02-13
ES2396583T3 (es) 2013-02-22
US20100125093A1 (en) 2010-05-20
CA2739992A1 (en) 2010-05-20
CO6361993A2 (es) 2012-01-20
IL212452A0 (en) 2011-06-30
HRP20130300T1 (hr) 2013-04-30
PT2358674E (pt) 2013-03-05
RU2011123890A (ru) 2012-12-20
US20130030020A1 (en) 2013-01-31
AU2009313949B2 (en) 2015-03-19
BRPI0921593B1 (pt) 2021-05-04
JP5506813B2 (ja) 2014-05-28
ES2397247T3 (es) 2013-03-05
SMT201200063B (it) 2013-01-14
AU2009313951B2 (en) 2015-03-12
US8247433B2 (en) 2012-08-21
IL212230A0 (en) 2011-06-30
AU2009313948A1 (en) 2010-05-20
US20100125141A1 (en) 2010-05-20
HRP20120897T1 (hr) 2012-12-31
HRP20120920T1 (hr) 2013-01-31
US10226454B2 (en) 2019-03-12
RU2011123875A (ru) 2012-12-20
BRPI0921596A2 (pt) 2018-03-20
PT2358675E (pt) 2012-12-12
TW201022206A (en) 2010-06-16
US10946006B2 (en) 2021-03-16
US8304433B2 (en) 2012-11-06
US20130030185A1 (en) 2013-01-31
US9073859B2 (en) 2015-07-07
EP2358676B1 (en) 2012-10-10
BRPI0921593B8 (pt) 2021-05-25
US10441579B2 (en) 2019-10-15
TWI441810B (zh) 2014-06-21
PT2358676E (pt) 2012-12-06
TWI461407B (zh) 2014-11-21
EP2358676A1 (en) 2011-08-24
SMT201300033B (it) 2013-05-06
EP2358675B9 (en) 2019-09-11
ES2401224T3 (es) 2013-04-17
AR074128A1 (es) 2010-12-22
CA2742114A1 (en) 2010-05-20
PL2358675T3 (pl) 2013-03-29
MY151211A (en) 2014-04-30
EP2358675A1 (en) 2011-08-24
EP2358674A1 (en) 2011-08-24
CN102216271A (zh) 2011-10-12
CY1113623T1 (el) 2016-06-22
US20190142816A1 (en) 2019-05-16
US11723900B2 (en) 2023-08-15
RU2515612C2 (ru) 2014-05-20
CN102209712A (zh) 2011-10-05
AU2009313948B2 (en) 2015-03-12
SG171311A1 (en) 2011-07-28
US8304432B2 (en) 2012-11-06
JP5598798B2 (ja) 2014-10-01
SI2358674T1 (sl) 2013-04-30
US10946007B2 (en) 2021-03-16
CY1113855T1 (el) 2016-07-27
US20210290608A1 (en) 2021-09-23
US20180050024A1 (en) 2018-02-22
TWI443087B (zh) 2014-07-01
KR101685186B1 (ko) 2016-12-09
NZ592543A (en) 2013-02-22
US8604058B2 (en) 2013-12-10
RU2503662C2 (ru) 2014-01-10
JP2014139209A (ja) 2014-07-31
SI2358675T1 (sl) 2013-01-31
KR20110082085A (ko) 2011-07-15
HK1160448A1 (en) 2012-08-17
BRPI0921596B1 (pt) 2021-10-26
TW201024263A (en) 2010-07-01
CN102216272B (zh) 2014-02-05
US20180055830A1 (en) 2018-03-01
US9162982B2 (en) 2015-10-20
MX2011005088A (es) 2011-06-01

Similar Documents

Publication Publication Date Title
AR074350A1 (es) Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CL2016000117A1 (es) Autotaxina inhibidores comprende un anillo heteroaromático-bencilamina ciclo basico
CY1118340T1 (el) Αναστολεις κινασης
UY29766A1 (es) Formas cristalinas delta y épsilon de mesilato de imatinib
AR097204A1 (es) Métodos de tratamiento de tumores sólidos
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
CL2013000850A1 (es) Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros.
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
PE20091199A1 (es) Derivado de piperazina que tiene afinidad por el receptor de histamina h3
NO20090250L (no) Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin med kombinert serotonin- og norepinefrin reopptaksinhibering for behandlingen av nevropatisk smerte
CL2013000785A1 (es) Compuestos 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il)pirimidin-4-ilamino)(-n,n-dimetilbenzamida o –n-metilbenzamida o –benzamida); composicion farmaceutica; metodo de preparacion; producto farmaceutico; metodo de tratamiento; uso para tratar un trastorno neurologico, entre otros.
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
UA97660C2 (ru) Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
CR11473A (es) Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UY33376A (es) Sal de tipo hemifumarato
ECSP10010150A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
CO6680652A2 (es) Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina
AR077692A1 (es) Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo

Legal Events

Date Code Title Description
FC Refusal